Last 12 months
Inside the activity.
0 purchase rows · 16 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 7 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 5 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 25, 2021 Filed Aug 26, 2021 23:28 UTC |
Salmon SeanEVP & Pres Diabetes/Cardiovasc
|
Exercise / conversionOrdinary Shares | 4,713 | $38.20 | $180,036.60 |
DisclosureSEC source: 0001127602-21-024367 · form4.xml · nonDerivative · entry 4 Salmon Sean · CIK 0001792380 · EVP & Pres Diabetes/Cardiovasc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,619 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 25, 2021 Filed Aug 26, 2021 23:28 UTC |
Salmon SeanEVP & Pres Diabetes/Cardiovasc
|
Exercise / conversionOrdinary Shares | 2,577 | $38.81 | $100,013.37 |
DisclosureSEC source: 0001127602-21-024367 · form4.xml · nonDerivative · entry 3 Salmon Sean · CIK 0001792380 · EVP & Pres Diabetes/Cardiovasc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,906 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 25, 2021 Filed Aug 26, 2021 23:28 UTC |
Salmon SeanEVP & Pres Diabetes/Cardiovasc
|
SaleOrdinary Shares | 21,129 | $134.08 | $2,832,976.32 |
DisclosureSEC source: 0001127602-21-024367 · form4.xml · nonDerivative · entry 2 Salmon Sean · CIK 0001792380 · EVP & Pres Diabetes/Cardiovasc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,329 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $134.05 to $134.16 inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 25, 2021 Filed Aug 26, 2021 23:28 UTC |
Salmon SeanEVP & Pres Diabetes/Cardiovasc
|
Exercise / conversionOrdinary Shares | 21,129 | $38.81 | $820,016.49 |
DisclosureSEC source: 0001127602-21-024367 · form4.xml · nonDerivative · entry 1 Salmon Sean · CIK 0001792380 · EVP & Pres Diabetes/Cardiovasc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,458 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 18:19 UTC |
Liddicoat John REVP & President of Americas
|
GrantPerformance Share Units · Derivative | 8,381 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-023102 · form4.xml · derivative · entry 5 Liddicoat John R · CIK 0001752060 · EVP & President of Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,381 Underlying: Performance Share Units · 8,381 shares Expires not disclosed F5 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F6 · shares: The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 8,381 shares will be issued. The actual number of shares to be issued could range from a low of 1,677 at minimum performance to a high of 16,762 shares at maximum performance. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F7 · derivative.exercise_date: Vests on August 2, 2024. F7 · derivative.expiration_date: Vests on August 2, 2024. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 18:19 UTC |
Liddicoat John REVP & President of Americas
|
GrantStock Option (Right to Buy) · Derivative | 1,085 | $0.00 Strike: $131.26 | $0.00 |
DisclosureSEC source: 0001127602-21-023102 · form4.xml · derivative · entry 4 Liddicoat John R · CIK 0001752060 · EVP & President of Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,085 Underlying: Ordinary Shares · 1,085 shares Expires 2031-08-02 F4 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 18:19 UTC |
Liddicoat John REVP & President of Americas
|
GrantStock Option (Right to Buy) · Derivative | 28,641 | $0.00 Strike: $131.26 | $0.00 |
DisclosureSEC source: 0001127602-21-023102 · form4.xml · derivative · entry 3 Liddicoat John R · CIK 0001752060 · EVP & President of Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,641 Underlying: Ordinary Shares · 28,641 shares Expires 2031-08-02 F4 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 18:19 UTC |
Liddicoat John REVP & President of Americas
|
GrantOrdinary Shares | 3,353 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-023102 · form4.xml · nonDerivative · entry 2 Liddicoat John R · CIK 0001752060 · EVP & President of Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,847 F3 · kind: The restrictions on the award shall lapse 100% on the third anniversary of the Grant Date. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 18:19 UTC |
Liddicoat John REVP & President of Americas
|
Tax withholdingOrdinary Shares | 3,258 | $131.31 | $427,807.98 |
DisclosureSEC source: 0001127602-21-023102 · form4.xml · nonDerivative · entry 1 Liddicoat John R · CIK 0001752060 · EVP & President of Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,494 F1 · balance_after: This amount has been adjusted to correct a mathematical error in exempt transactions such as dividend reinvestment. F2 · balance_after: This balance increased by 284 shares due to exempt transactions such as dividend reinvestment and employee stock purchase plan. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 18:29 UTC |
WHITE ROBERT JOHNEVP & Pres. Medical Surgical
|
GrantPerformance Share Units · Derivative | 15,237 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-023109 · form4.xml · derivative · entry 6 WHITE ROBERT JOHN · CIK 0001726709 · EVP & Pres. Medical Surgical 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,237 Underlying: Performance Share Units · 15,237 shares Expires not disclosed F5 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F6 · shares: The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 15,237 shares will be issued. The actual number of shares to be issued could range from a low of 3,048 at minimum performance to a high of 30,474 shares at maximum performance. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F7 · derivative.exercise_date: Vests on August 2, 2024. F7 · derivative.expiration_date: Vests on August 2, 2024. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 18:29 UTC |
WHITE ROBERT JOHNEVP & Pres. Medical Surgical
|
GrantStock Option (Right to Buy) · Derivative | 1,085 | $0.00 Strike: $131.26 | $0.00 |
DisclosureSEC source: 0001127602-21-023109 · form4.xml · derivative · entry 5 WHITE ROBERT JOHN · CIK 0001726709 · EVP & Pres. Medical Surgical 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,085 Underlying: Ordinary Shares · 1,085 shares Expires 2031-08-02 F4 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 18:29 UTC |
WHITE ROBERT JOHNEVP & Pres. Medical Surgical
|
GrantStock Option (Right to Buy) · Derivative | 52,074 | $0.00 Strike: $131.26 | $0.00 |
DisclosureSEC source: 0001127602-21-023109 · form4.xml · derivative · entry 4 WHITE ROBERT JOHN · CIK 0001726709 · EVP & Pres. Medical Surgical 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,074 Underlying: Ordinary Shares · 52,074 shares Expires 2031-08-02 F4 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 18:29 UTC |
WHITE ROBERT JOHNEVP & Pres. Medical Surgical
|
GrantOrdinary Shares | 6,095 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-023109 · form4.xml · nonDerivative · entry 2 WHITE ROBERT JOHN · CIK 0001726709 · EVP & Pres. Medical Surgical 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,769 F2 · kind: The restrictions on the award shall lapse 100% on the third anniversary of the Grant Date. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 18:29 UTC |
WHITE ROBERT JOHNEVP & Pres. Medical Surgical
|
Tax withholdingOrdinary Shares | 4,897 | $131.31 | $643,025.07 |
DisclosureSEC source: 0001127602-21-023109 · form4.xml · nonDerivative · entry 1 WHITE ROBERT JOHN · CIK 0001726709 · EVP & Pres. Medical Surgical 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,674 F1 · balance_after: This balance increased by 649 shares due to exempt transactions such as dividend reinvestment and employee stock purchase plan. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 18:25 UTC |
Surface Carol ASVP, Chief HR Officer
|
GrantPerformance Share Units · Derivative | 9,143 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-023106 · form4.xml · derivative · entry 6 Surface Carol A · CIK 0001485966 · SVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,143 Underlying: Performance Share Units · 9,143 shares Expires not disclosed F5 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F6 · shares: The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 9,143 shares will be issued. The actual number of shares to be issued could range from a low of 1,829 at minimum performance to a high of 18,286 shares at maximum performance. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F7 · derivative.exercise_date: Vests on August 2, 2024. F7 · derivative.expiration_date: Vests on August 2, 2024. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 18:25 UTC |
Surface Carol ASVP, Chief HR Officer
|
GrantStock Option (Right to Buy) · Derivative | 1,085 | $0.00 Strike: $131.26 | $0.00 |
DisclosureSEC source: 0001127602-21-023106 · form4.xml · derivative · entry 5 Surface Carol A · CIK 0001485966 · SVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,085 Underlying: Ordinary Shares · 1,085 shares Expires 2031-08-02 F4 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 18:25 UTC |
Surface Carol ASVP, Chief HR Officer
|
GrantStock Option (Right to Buy) · Derivative | 31,245 | $0.00 Strike: $131.26 | $0.00 |
DisclosureSEC source: 0001127602-21-023106 · form4.xml · derivative · entry 4 Surface Carol A · CIK 0001485966 · SVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,245 Underlying: Ordinary Shares · 31,245 shares Expires 2031-08-02 F4 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 18:25 UTC |
Surface Carol ASVP, Chief HR Officer
|
GrantOrdinary Shares | 3,657 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-023106 · form4.xml · nonDerivative · entry 2 Surface Carol A · CIK 0001485966 · SVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,327 F2 · kind: The restrictions on the award shall lapse 100% on the third anniversary of the Grant Date. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 18:25 UTC |
Surface Carol ASVP, Chief HR Officer
|
Tax withholdingOrdinary Shares | 3,997 | $131.31 | $524,846.07 |
DisclosureSEC source: 0001127602-21-023106 · form4.xml · nonDerivative · entry 1 Surface Carol A · CIK 0001485966 · SVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,670 F1 · balance_after: This balance increased by 517 shares due to exempt transactions such as dividend reinvestment and employee stock purchase plan. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 22:28 UTC |
Wall Brett A.EVP & Pres Neuroscience
|
GrantPerformance Share Units · Derivative | 13,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-023108 · form4.xml · derivative · entry 5 Wall Brett A. · CIK 0001473812 · EVP & Pres Neuroscience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,333 Underlying: Performance Share Units · 13,333 shares Expires not disclosed F5 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F6 · shares: The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 13,333 shares will be issued. The actual number of shares to be issued could range from a low of 2,667 shares at minimum performance to a high of 26,666 shares at maximum performance. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F7 · derivative.exercise_date: Vests on August 2, 2024. F7 · derivative.expiration_date: Vests on August 2, 2024. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 22:28 UTC |
Wall Brett A.EVP & Pres Neuroscience
|
GrantStock Option (Right to Buy) · Derivative | 1,085 | $0.00 Strike: $131.26 | $0.00 |
DisclosureSEC source: 0001127602-21-023108 · form4.xml · derivative · entry 4 Wall Brett A. · CIK 0001473812 · EVP & Pres Neuroscience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,085 Underlying: Ordinary Shares · 1,085 shares Expires 2031-08-02 F4 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 22:28 UTC |
Wall Brett A.EVP & Pres Neuroscience
|
GrantStock Option (Right to Buy) · Derivative | 45,565 | $0.00 Strike: $131.26 | $0.00 |
DisclosureSEC source: 0001127602-21-023108 · form4.xml · derivative · entry 3 Wall Brett A. · CIK 0001473812 · EVP & Pres Neuroscience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,565 Underlying: Ordinary Shares · 45,565 shares Expires 2031-08-02 F4 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 22:28 UTC |
Wall Brett A.EVP & Pres Neuroscience
|
GrantOrdinary Shares | 5,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-023108 · form4.xml · nonDerivative · entry 2 Wall Brett A. · CIK 0001473812 · EVP & Pres Neuroscience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,395 F3 · kind: The restrictions on the award shall lapse 100% on the third anniversary of the Grant Date. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 22:28 UTC |
Wall Brett A.EVP & Pres Neuroscience
|
Tax withholdingOrdinary Shares | 1,482 | $131.31 | $194,601.42 |
DisclosureSEC source: 0001127602-21-023108 · form4.xml · nonDerivative · entry 1 Wall Brett A. · CIK 0001473812 · EVP & Pres Neuroscience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,062 F1 · balance_after: This amount has been adjusted to correct a mathematical error in exempt transactions such as dividend reinvestment. F2 · balance_after: This balance increased by 83 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 22:16 UTC |
Kuntz RichardSVP & Chief Medical & Science
|
GrantPerformance Share Units · Derivative | 12,571 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-023100 · form4.xml · derivative · entry 5 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,571 Underlying: Performance Share Units · 12,571 shares Expires not disclosed F4 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F5 · shares: The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 12,571 shares will be issued. The actual number of shares to be issued could range from a low of 2,515 at minimum performance to a high of 25,142 shares at maximum performance. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F6 · derivative.exercise_date: Vests on August 2, 2024. F6 · derivative.expiration_date: Vests on August 2, 2024. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 22:16 UTC |
Kuntz RichardSVP & Chief Medical & Science
|
GrantStock Option (Right to Buy) · Derivative | 1,085 | $0.00 Strike: $131.26 | $0.00 |
DisclosureSEC source: 0001127602-21-023100 · form4.xml · derivative · entry 4 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,085 Underlying: Ordinary Shares · 1,085 shares Expires 2031-08-02 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 22:16 UTC |
Kuntz RichardSVP & Chief Medical & Science
|
GrantStock Option (Right to Buy) · Derivative | 42,961 | $0.00 Strike: $131.26 | $0.00 |
DisclosureSEC source: 0001127602-21-023100 · form4.xml · derivative · entry 3 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,961 Underlying: Ordinary Shares · 42,961 shares Expires 2031-08-02 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 22:16 UTC |
Kuntz RichardSVP & Chief Medical & Science
|
GrantOrdinary Shares | 5,029 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-023100 · form4.xml · nonDerivative · entry 2 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,915 F2 · kind: The restrictions on the award shall lapse 100% on the third anniversary of the Grant Date. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 22:16 UTC |
Kuntz RichardSVP & Chief Medical & Science
|
Tax withholdingOrdinary Shares | 4,905 | $131.31 | $644,075.55 |
DisclosureSEC source: 0001127602-21-023100 · form4.xml · nonDerivative · entry 1 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,886 F1 · balance_after: This balance increased by 782 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 22:23 UTC |
PARKHILL KAREN LEVP & Chief Financial Officer
|
GrantPerformance Share Units · Derivative | 17,904 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-023104 · form4.xml · derivative · entry 8 PARKHILL KAREN L · CIK 0001527660 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,904 Underlying: Performance Share Units · 17,904 shares Expires not disclosed F5 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F6 · shares: The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 17,904 shares will be issued. The actual number of shares to be issued could range from a low of 3,581 at minimum performance to a high of 35,808 shares at maximum performance. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F7 · derivative.exercise_date: Vests on August 2, 2024. F7 · derivative.expiration_date: Vests on August 2, 2024. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 22:23 UTC |
PARKHILL KAREN LEVP & Chief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 1,085 | $0.00 Strike: $131.26 | $0.00 |
DisclosureSEC source: 0001127602-21-023104 · form4.xml · derivative · entry 7 PARKHILL KAREN L · CIK 0001527660 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,085 Underlying: Ordinary Shares · 1,085 shares Expires 2031-08-02 F4 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 22:23 UTC |
PARKHILL KAREN LEVP & Chief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 61,187 | $0.00 Strike: $131.26 | $0.00 |
DisclosureSEC source: 0001127602-21-023104 · form4.xml · derivative · entry 6 PARKHILL KAREN L · CIK 0001527660 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,187 Underlying: Ordinary Shares · 61,187 shares Expires 2031-08-02 F4 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 22:23 UTC |
PARKHILL KAREN LEVP & Chief Financial Officer
|
GrantOrdinary Shares | 7,162 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-023104 · form4.xml · nonDerivative · entry 2 PARKHILL KAREN L · CIK 0001527660 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,833 F3 · kind: The restrictions on the award shall lapse 100% on the third anniversary of the Grant Date. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 22:23 UTC |
PARKHILL KAREN LEVP & Chief Financial Officer
|
Tax withholdingOrdinary Shares | 6,839 | $131.31 | $898,029.09 |
DisclosureSEC source: 0001127602-21-023104 · form4.xml · nonDerivative · entry 1 PARKHILL KAREN L · CIK 0001527660 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,671 F1 · balance_after: This amount has been adjusted to correct a mathematical error in exempt transactions such as dividend reinvestment. F2 · balance_after: This balance increased by 198 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 22:18 UTC |
Lerman Bradley ESVP General Counsel & Corp Sec
|
GrantPerformance Share Units · Derivative | 15,047 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-023101 · form4.xml · derivative · entry 6 Lerman Bradley E · CIK 0001559405 · SVP General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,047 Underlying: Performance Share Units · 15,047 shares Expires not disclosed F5 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F6 · shares: The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 15,047 shares will be issued. The actual number of shares to be issued could range from a low of 3,010 at minimum performance to a high of 30,094 shares at maximum performance. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F7 · derivative.exercise_date: Vests on August 2, 2024. F7 · derivative.expiration_date: Vests on August 2, 2024. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 22:18 UTC |
Lerman Bradley ESVP General Counsel & Corp Sec
|
GrantStock Option (Right to Buy) · Derivative | 1,085 | $0.00 Strike: $131.26 | $0.00 |
DisclosureSEC source: 0001127602-21-023101 · form4.xml · derivative · entry 5 Lerman Bradley E · CIK 0001559405 · SVP General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,085 Underlying: Ordinary Shares · 1,085 shares Expires 2031-08-02 F4 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 22:18 UTC |
Lerman Bradley ESVP General Counsel & Corp Sec
|
GrantStock Option (Right to Buy) · Derivative | 51,423 | $0.00 Strike: $131.26 | $0.00 |
DisclosureSEC source: 0001127602-21-023101 · form4.xml · derivative · entry 4 Lerman Bradley E · CIK 0001559405 · SVP General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,423 Underlying: Ordinary Shares · 51,423 shares Expires 2031-08-02 F4 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 22:18 UTC |
Lerman Bradley ESVP General Counsel & Corp Sec
|
GrantOrdinary Shares | 6,019 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-023101 · form4.xml · nonDerivative · entry 3 Lerman Bradley E · CIK 0001559405 · SVP General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,763 F3 · kind: The restrictions on the award shall lapse 100% on the third anniversary of the Grant Date. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 22:18 UTC |
Lerman Bradley ESVP General Counsel & Corp Sec
|
Tax withholdingOrdinary Shares | 5,450 | $131.31 | $715,639.50 |
DisclosureSEC source: 0001127602-21-023101 · form4.xml · nonDerivative · entry 2 Lerman Bradley E · CIK 0001559405 · SVP General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,744 Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 22:18 UTC |
Lerman Bradley ESVP General Counsel & Corp Sec
|
SaleOrdinary Shares | 4,000 | $131.52 | $526,080.00 |
DisclosureSEC source: 0001127602-21-023101 · form4.xml · nonDerivative · entry 1 Lerman Bradley E · CIK 0001559405 · SVP General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,194 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · balance_after: This balance increased by 651 shares due to exempt transactions such as dividend reinvestment and employee stock purchase plan. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 22:20 UTC |
Martha GeoffreyDirector · CEO
|
GrantPerformance Share Units · Derivative | 47,616 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-023103 · form4.xml · derivative · entry 4 Martha Geoffrey · CIK 0001560409 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,616 Underlying: Performance Share Units · 47,616 shares Expires not disclosed F4 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F5 · shares: The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 47,616 shares will be issued. The actual number of shares to be issued could range from a low of 9,524 at minimum performance to a high of 95,232 shares at maximum performance. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F6 · derivative.exercise_date: Vests on August 2, 2024. F6 · derivative.expiration_date: Vests on August 2, 2024. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 22:20 UTC |
Martha GeoffreyDirector · CEO
|
GrantStock Option (Right to Buy) · Derivative | 162,731 | $0.00 Strike: $131.26 | $0.00 |
DisclosureSEC source: 0001127602-21-023103 · form4.xml · derivative · entry 3 Martha Geoffrey · CIK 0001560409 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,731 Underlying: Ordinary Shares · 162,731 shares Expires 2031-08-02 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 22:20 UTC |
Martha GeoffreyDirector · CEO
|
GrantOrdinary Shares | 19,047 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-023103 · form4.xml · nonDerivative · entry 2 Martha Geoffrey · CIK 0001560409 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,836 F2 · kind: The restrictions on the award shall lapse 100% on the third anniversary of the Grant Date. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 22:20 UTC |
Martha GeoffreyDirector · CEO
|
Tax withholdingOrdinary Shares | 5,450 | $131.31 | $715,639.50 |
DisclosureSEC source: 0001127602-21-023103 · form4.xml · nonDerivative · entry 1 Martha Geoffrey · CIK 0001560409 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,789 F1 · balance_after: This balance increased by 291 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 18:26 UTC |
TEN HOEDT ROBEVP & President EMEA
|
GrantPerformance Share Units · Derivative | 11,047 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-023107 · form4.xml · derivative · entry 5 TEN HOEDT ROB · CIK 0001610036 · EVP & President EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,047 Underlying: Performance Share Units · 11,047 shares Expires not disclosed F5 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F6 · shares: The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 11,047 shares will be issued. The actual number of shares to be issued could range from a low of 2,210 shares at minimum performance to a high of 22,094 shares at maximum performance. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F7 · derivative.exercise_date: Vests on August 2, 2024. F7 · derivative.expiration_date: Vests on August 2, 2024. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 18:26 UTC |
TEN HOEDT ROBEVP & President EMEA
|
GrantStock Option (Right to Buy) · Derivative | 1,085 | $0.00 Strike: $131.26 | $0.00 |
DisclosureSEC source: 0001127602-21-023107 · form4.xml · derivative · entry 4 TEN HOEDT ROB · CIK 0001610036 · EVP & President EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,085 Underlying: Ordinary Shares · 1,085 shares Expires 2031-08-02 F4 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 18:26 UTC |
TEN HOEDT ROBEVP & President EMEA
|
GrantStock Option (Right to Buy) · Derivative | 37,754 | $0.00 Strike: $131.26 | $0.00 |
DisclosureSEC source: 0001127602-21-023107 · form4.xml · derivative · entry 3 TEN HOEDT ROB · CIK 0001610036 · EVP & President EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,754 Underlying: Ordinary Shares · 37,754 shares Expires 2031-08-02 F4 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 18:26 UTC |
TEN HOEDT ROBEVP & President EMEA
|
GrantOrdinary Shares | 4,419 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-023107 · form4.xml · nonDerivative · entry 2 TEN HOEDT ROB · CIK 0001610036 · EVP & President EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,489 F3 · kind: The restrictions on the award shall lapse 100% on the third anniversary of the Grant Date. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 18:26 UTC |
TEN HOEDT ROBEVP & President EMEA
|
Tax withholdingOrdinary Shares | 3,908 | $131.31 | $513,159.48 |
DisclosureSEC source: 0001127602-21-023107 · form4.xml · nonDerivative · entry 1 TEN HOEDT ROB · CIK 0001610036 · EVP & President EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,070 F1 · balance_after: This amount has been adjusted to correct a mathematical error in exempt transactions such as dividend reinvestment. F2 · balance_after: This balance increased by 245 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 22:24 UTC |
Salmon SeanEVP & Pres Diabetes/Cardiovasc
|
GrantPerformance Share Units · Derivative | 13,714 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-023105 · form4.xml · derivative · entry 5 Salmon Sean · CIK 0001792380 · EVP & Pres Diabetes/Cardiovasc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,714 Underlying: Performance Share Units · 13,714 shares Expires not disclosed F5 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F6 · shares: The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 13,714 shares will be issued. The actual number of shares to be issued could range from a low of 2,743 at minimum performance to a high of 27,428 shares at maximum performance. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F7 · derivative.exercise_date: Vests on August 2, 2024. F7 · derivative.expiration_date: Vests on August 2, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.